Novel recombinant oncolytic vaccinia virus for blocking immune inspection point and activating immune co-stimulation, construction method for novel recombinant oncolytic vaccinia virus and application of Novel recombinant oncolytic vaccinia virus

Abstract

The invention discloses a novel recombinant oncolytic vaccinia virus for blocking immune inspection point and activating immune co-stimulation signal channels, a construction method for the novel recombinant oncolytic vaccinia virus and application of the novel recombinant oncolytic vaccinia virus. The novel recombinant oncolytic vaccinia virus for blocking the immune inspection point and activating the immune co-stimulation signal channels can selectively replicate in tumor cells and dissolve the tumor cells and meanwhile express and secrete a soluble protein sCD155; and the soluble protein sCD155 is an extracellular region of a protein CD155 and can specifically bond acceptors TIGIT and CD226 of the protein CD155. The novel recombinant oncolytic vaccinia virus VV-sCD155 disclosed by theinvention has multiple antitumor actions of dissolving tumors, activating antitumor immunization and the like, only selectively replicates in the tumor cells, has very high safety and has a good antitumor drug development prospect.

Description

technical field [0001] The invention relates to the field of tumor biotechnology, in particular to a novel recombinant oncolytic vaccinia virus that blocks immune checkpoints and activates immune co-stimulatory signaling pathways, and its construction method and application. Background technique [0002] Cancer is one of the most harmful diseases to human life and health, and millions of people die of cancer every year. Many patients are already in the middle and late stage at the time of diagnosis and thus lose the chance of surgical treatment. Traditional radiotherapy and chemotherapy have not made breakthroughs, and even small-molecule targeted drugs are still facing the huge challenge of short-term recurrence. [0003] In the past ten years, exciting results have emerged in the clinical research of anti-tumor immunotherapy, bringing hope to cancer patients again. As early as 1090, German scientist (Nobel Prize winner) Paul Ehrlich proposed that the immune system has th...

AI Technical Summary

Problems solved by technology

[0007] Currently, there is a lack of a recombinant oncolytic vaccinia virus capable of both blocking immune checkpoints and activating immune co-stimulatory pathways

Images